Adicet bio reports positive data from ongoing adi-001 phase 1 trial in patients with relapsed or refractory aggressive b-cell non-hodgkin's lymphoma (nhl)

Redwood city, calif. & boston--( business wire )--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today announced positive safety and efficacy data from the company's ongoing phase 1 study of adi-001 for the potential treatment of relapsed or refractory b-cell nhl. the company believes these data continue to support the potential of adicet's investigational gamma delta car t cell therapy to provide significant benefit both in terms of anti-tumor activity and safety. based on the study findings as of a december 5, 2022 data-cut date, adicet plans to transition adi-001 into a potentially pivotal program in the second quarter of 2023.
ACET Ratings Summary
ACET Quant Ranking